Meditor Group LTD Upped By $19.18 Million Its Esperion Therapeutics (ESPR) Holding; Cannabis Science (CBIS) Has 2.5 Sentiment

July 12, 2018 - By Ira Colvard

Cannabis Science, Inc. (OTCMKTS:CBIS) Logo

Cannabis Science Inc (CBIS) investors sentiment increased to 2.5 in Q1 2018. It’s up 1.17, from 1.33 in 2017Q4. The ratio has increased, as 5 hedge funds increased or started new positions, while 2 sold and trimmed stakes in Cannabis Science Inc. The hedge funds in our database now have: 264,180 shares, down from 277,539 shares in 2017Q4. Also, the number of hedge funds holding Cannabis Science Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 1 Increased: 1 New Position: 4.

Meditor Group Ltd increased Esperion Therapeutics Inc (ESPR) stake by 11.47% reported in 2018Q1 SEC filing. Meditor Group Ltd acquired 266,400 shares as Esperion Therapeutics Inc (ESPR)’s stock declined 53.51%. The Meditor Group Ltd holds 2.59M shares with $187.28 million value, up from 2.32M last quarter. Esperion Therapeutics Inc now has $1.10 billion valuation. The stock decreased 0.77% or $0.32 during the last trading session, reaching $41.23. About 684,655 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 12.80% since July 12, 2017 and is uptrending. It has outperformed by 0.23% the S&P500. Some Historical ESPR News: 07/03/2018 – Esperion: LDL-C Lowering for Bempedoic Acid Group Was 23 % From Baseline; 22/05/2018 – Esperion Therapeutics Presenting at UBS Conference Tomorrow; 04/04/2018 – Esperion Therapeutics Non-Deal Roadshow Set By JMP for Apr. 11; 10/05/2018 – Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference; 24/05/2018 – The Klein Law Firm Announces a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR); 13/04/2018 – Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4); 02/05/2018 – Esperion: Positive Top-Line Results From Phase 3 Study of Bempedoic Acid; 22/05/2018 – Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference; 27/03/2018 – Esperion Therapeutics Access Event Set By Chardan for Apr. 3; 27/03/2018 – ESPERION THERAPEUTICS INC – STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING

Investors sentiment increased to 1.5 in Q1 2018. Its up 0.17, from 1.33 in 2017Q4. It increased, as 14 investors sold ESPR shares while 46 reduced holdings. 36 funds opened positions while 54 raised stakes. 24.56 million shares or 8.25% more from 22.69 million shares in 2017Q4 were reported. Atlantic Grp Limited Liability Corporation reported 1,000 shares stake. Parkside Commercial Bank And Trust accumulated 0.01% or 500 shares. 4,771 were reported by First Mercantile Tru. Gam Holdg Ag holds 198,600 shares or 0.51% of its portfolio. Spark Management Limited Liability Com reported 43,400 shares stake. Victory Management Inc reported 282 shares stake. Aperio Group Incorporated Limited Liability accumulated 5,995 shares or 0% of the stock. Nj State Employees Deferred Compensation Plan accumulated 11,125 shares. North Star Invest Mngmt, Illinois-based fund reported 70 shares. Schwab Charles accumulated 95,442 shares. D E Shaw Inc has invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Vanguard reported 1.49M shares. Amundi Pioneer Asset invested in 0.03% or 294,730 shares. Bailard Inc invested in 59,300 shares. State Board Of Administration Of Florida Retirement Systems invested in 0% or 9,741 shares.

Among 14 analysts covering Esperion (NASDAQ:ESPR), 7 have Buy rating, 3 Sell and 4 Hold. Therefore 50% are positive. Esperion had 19 analyst reports since January 15, 2018 according to SRatingsIntel. Cowen & Co maintained it with “Buy” rating and $9500 target in Tuesday, March 27 report. The firm earned “Underweight” rating on Thursday, May 3 by JP Morgan. Deutsche Bank maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Thursday, May 3. Deutsche Bank has “Buy” rating and $7500 target. On Monday, March 19 the stock rating was maintained by Jefferies with “Buy”. The company was downgraded on Wednesday, May 2 by Bank of America. The firm has “Buy” rating given on Wednesday, January 17 by UBS. The rating was maintained by Chardan Capital Markets on Tuesday, March 27 with “Neutral”. The rating was maintained by Credit Suisse on Friday, May 4 with “Outperform”. The stock has “Buy” rating by Needham on Wednesday, February 21. The stock has “Neutral” rating by JP Morgan on Wednesday, February 21.

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: which released: “Thoughts From Esperion Therapeutics (ESPR) Analyst Day – Needham” on July 11, 2018, also with their article: “SHAREHOLDER ALERT – LC ESPR INWK FLEX KLIC SYMC MFGP FLR REPH: The Law Offices of Vincent Wong …” published on July 02, 2018, published: “Esperion (ESPR) Defended at Jefferies Following KOL Commentary” on July 10, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: and their article: “Esperion to Host Analyst and Investor Day Event on July 10” published on July 03, 2018 as well as‘s news article titled: “CLASS ACTION UPDATE for ESPR, SYMC, and PPG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on …” with publication date: July 05, 2018.

The stock decreased 2.11% or $0.001149 during the last trading session, reaching $0.053401. About shares traded. Cannabis Science, Inc. (CBIS) has 0.00% since July 12, 2017 and is . It has underperformed by 12.57% the S&P500.

Donaldson Capital Management Llc holds 0% of its portfolio in Cannabis Science, Inc. for 99,780 shares. Edge Wealth Management Llc owns 15,000 shares or 0% of their US portfolio. Moreover, Fisher Asset Management Llc has 0% invested in the company for 12,000 shares. The Texas-based Frontier Investment Mgmt Co has invested 0% in the stock. Massmutual Trust Co Fsb Adv, a Connecticut-based fund reported 8,400 shares.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $136.27 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts